Literature DB >> 19969053

Biochemical and biopharmaceutical properties of PEGylated uricase.

Débora da Silva Freitas1, Patrick Jack Spencer, Ruth Camargo Vassão, José Abrahão-Neto.   

Abstract

PEGylation is a successful strategy for improving the biochemical and biopharmaceutical properties of proteins and peptides through the covalent attachment of polyethylene glycol chains. In this work, purified recombinant uricase from Candida sp. (UC-r) was modified by PEGylation with metoxypolyethilenoglycol-p-nitrophenyl-carbonate (mPEG-pNP) and metoxypolyethyleneglycol-4,6-dichloro-s-triazine (mPEG-CN). The UC-r-mPEG-pNP and UC-r-mPEG-CN conjugates retained 87% and 75% enzyme activity respectively. The K(M) values obtained 2.7x10(-5) M (mPEG-pNP) or 3.0x10(-5) M (mPEG-CN) for the conjugates as compared to 5.4x10(-5) M for the native UC-r, suggesting enhancement in the substrate affinity of the enzyme attached. The effects of pH and temperature on PEGylated UC-r indicated that the conjugates were more active at close physiological pH and were stable up to 70 degrees C. Spectroscopic study performed by circular dichroism at 20 degrees C and 50 degrees C did not show any relevant difference in protein structure between native and PEGylated UC-r. In rabbit and Balb/c mice, the native UC-r elicited an intense immune response being highly immunogenic. On the other hand, the PEGylated UC-r when injected chronically in mice did not induce any detectable antibody response. This indicates sufficient reduction of the immunogenicity this enzyme by mPEG-pNP or mPEG-CN conjugation, making it suitable for a possible therapeutical use. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19969053     DOI: 10.1016/j.ijpharm.2009.11.034

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  5 in total

1.  Site-specific albumination of a therapeutic protein with multi-subunit to prolong activity in vivo.

Authors:  Sung In Lim; Young S Hahn; Inchan Kwon
Journal:  J Control Release       Date:  2015-04-07       Impact factor: 9.776

2.  Recent developments in protein and peptide parenteral delivery approaches.

Authors:  Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Ther Deliv       Date:  2014-03

3.  Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase.

Authors:  Chun Zhang; Kai Fan; Xuefeng Ma; Dongzhi Wei
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

4.  Recombinant Peptide Production Platform Coupled with Site-Specific Albumin Conjugation Enables a Convenient Production of Long-Acting Therapeutic Peptide.

Authors:  Mijeong Bak; Junyong Park; Kiyoon Min; Jinhwan Cho; Jihyoun Seong; Young S Hahn; Giyoong Tae; Inchan Kwon
Journal:  Pharmaceutics       Date:  2020-04-16       Impact factor: 6.321

5.  Improved biological properties and hypouricemic effects of uricase from Candida utilis loaded in novel alkaline enzymosomes.

Authors:  Qun-You Tan; Jing-Qing Zhang; Na Wang; Hong Yang; Xiaoling Li; Hua-Rong Xiong; Jian-Yong Wu; Chun-Jing Zhao; Hong Wang; Hua-Feng Yin
Journal:  Int J Nanomedicine       Date:  2012-07-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.